Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis

Summary

To establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately active ulcerative colitis after 6 weeks of therapy.

Timeline

Start

2006-05

Primary completion

2007-07

Completion

2007-11

Drugs

Indications